<DOC>
	<DOCNO>NCT01552122</DOCNO>
	<brief_summary>This study evaluate therapeutic effect safety odanacatib bone mineral density osteoporotic postmenopausal woman previously treat alendronate .</brief_summary>
	<brief_title>Efficacy Safety Odanacatib Postmenopausal Women Previously Treated With Alendronate ( MK-0822-050 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>In good general health , postmenopausal least 5 year Diagnosed postmenopausal osteoporosis Currently take alendronate least 3 year treatment osteoporosis One hip free orthopedic hardware ( ie , total hip device , hip pin ) ; anatomy suitable undergo dualemission Xray absorptiometry ( DXA ) scan ( ie , bone mineral density scan ) Agrees use medication treatment osteoporosis except provide participant study Evidence metabolic bone disorder History malignancy ( cancer ) 5 year less Active thyroid disease manage medication Severe renal insufficiency ( kidney disease ) , myocardial infarction , unstable angina , stroke revascularization , untreated malabsorption syndrome , and/or osteonecrosis jaw , anticipate undergo major dental procedure ( e.g . dental extraction implantation ) Use , misuse , abuse , and/or addiction illicit drug and/or recent history ( within last year ) drug alcohol abuse dependence Use estrogen without progestin and/or raloxifene ( ie , Evista® ) tamoxifen ( ie , Nolvadex® , Tamofen® ) Use oral bisphosphonate therapy alendronate ; intravenous bisphosphonates ( zoledronate , ibandronate , pamidronate ) ; form calcitonin intranasal ; anabolic steroid ; and/or Strontiumcontaining product ( ie , Osteovalin™ )</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>